EP Patent

EP0626853A1 — Use of substituted adenine derivatives for treating multiple sclerosis

Assigned to Scripps Research Institute · Expires 1994-12-07 · 31y expired

What this patent protects

The treatment of patients suffering from multiple sclerosis with the aid of therapeutic agents containing substituted adenine derivatives, such as 2-chloro-2'-deoxyadenosine, has a significant ameliorative effect on the pathological state.

USPTO Abstract

The treatment of patients suffering from multiple sclerosis with the aid of therapeutic agents containing substituted adenine derivatives, such as 2-chloro-2'-deoxyadenosine, has a significant ameliorative effect on the pathological state.

Drugs covered by this patent

Patent Metadata

Patent number
EP0626853A1
Jurisdiction
EP
Classification
—
Expires
1994-12-07
Drug substance claim
No
Drug product claim
No
Assignee
Scripps Research Institute
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.